Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00019708 Extranodal Marg...
Nodal Marginal ...
Non-Hodgkin Lym...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
tanespimycin
19 Years - National Cancer Institute (NCI) View Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation NCT00003056 Leukemia
Lymphoma
Graft Versus Ho...
cyclosporine
cyclosporine an...
18 Years - 55 Years Takeda View Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer NCT00546377 Leukemia
Lymphoma
filgrastim
pegfilgrastim
rituximab
sargramostim
cyclophosphamid...
mitoxantrone hy...
pentostatin
fluorescence in...
gene rearrangem...
polymerase chai...
protein express...
flow cytometry
biopsy
18 Years - 120 Years Memorial Sloan Kettering Cancer Center View Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease NCT00176475 Leukemia
Lymphoma
Multiple Myelom...
rituximab
therapeutic all...
18 Years - Rutgers, The State University of New Jersey View Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation NCT00003143 Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center View Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma NCT00244946 Lymphoma
therapeutic aut...
carmustine
cytarabine
etoposide
melphalan
peripheral bloo...
15 Years - 70 Years Barbara Ann Karmanos Cancer Institute View Bone Marrow Transplantation in Treating Patients With Lymphoma NCT00002829 Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 Years M.D. Anderson Cancer Center View Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma NCT00538187 Adult Non-Hodgk...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
obatoclax mesyl...
bortezomib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Beta Alethine in Treating Patients With Low-Grade Lymphoma NCT00007839 Lymphoma
beta alethine
18 Years - National Cancer Institute (NCI) View Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. NCT03150329 Grade 3b Follic...
Recurrent B-Cel...
Recurrent Class...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Prima...
Recurrent Trans...
Refractory B-Ce...
Refractory Clas...
Refractory Diff...
Refractory Foll...
Refractory Prim...
Refractory Tran...
Laboratory Biom...
Pembrolizumab
Vorinostat
18 Years - City of Hope Medical Center View Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00119392 B-cell Chronic ...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Waldenström Mac...
rituximab
cyclosporine
fludarabine pho...
mycophenolate m...
yttrium Y 90 ib...
peripheral bloo...
allogeneic hema...
total-body irra...
18 Years - Fred Hutchinson Cancer Center View Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma NCT00017381 Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Extranodal Marg...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Stage I Adult D...
Stage I Adult D...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenström Mac...
rituximab
cyclophosphamid...
filgrastim
yttrium Y 90 ib...
peripheral bloo...
18 Years - 70 Years National Cancer Institute (NCI) View Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma NCT00020462 Lymphoma
aldesleukin
autologous tumo...
18 Years - National Cancer Institute (NCI) View Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma NCT00002649 Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
aldesleukin
filgrastim
cyclophosphamid...
etoposide
radiation thera...
peripheral bloo...
bone marrow abl...
16 Years - 60 Years National Cancer Institute (NCI) View Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma NCT00980395 Lymphoma
Mantle Cell Lym...
Indolent Lympho...
SLL
rituximab
bortezomib
cladribine
18 Years - University of Arizona View Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma NCT00265928 Lymphoma
bortezomib
rituximab
antibody therap...
biological ther...
enzyme inhibito...
monoclonal anti...
18 Years - National Cancer Institute (NCI) View SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma NCT00101244 Adult Grade III...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
ispinesib
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma NCT00334438 Lymphoma
rituximab
bortezomib
yttrium Y 90 ib...
Indium 111 ibri...
18 Years - 120 Years UNC Lineberger Comprehensive Cancer Center View Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202 NCT00896662 Lymphoma
Solid Tumor
immunologic tec...
laboratory biom...
pharmacological...
18 Years - Vanderbilt-Ingram Cancer Center View Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00015912 Recurrent Grade...
Recurrent Grade...
recombinant int...
thalidomide
laboratory biom...
18 Years - National Cancer Institute (NCI) View Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma NCT00397800 Lymphoma
rituximab
cyclophosphamid...
fludarabine pho...
yttrium Y 90 ib...
50 Years - 75 Years Technical University of Munich View Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma NCT00005601 Lymphoma
rituximab
cisplatin
cytarabine
dexamethasone
sargramostim
18 Years - Alliance for Clinical Trials in Oncology View Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00007852 Lymphoma
rituximab
carmustine
cytarabine
etoposide
melphalan
autologous hema...
19 Years - University of Nebraska View Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma NCT00006039 Lymphoma
Small Intestine...
pegylated inter...
18 Years - Memorial Sloan Kettering Cancer Center View Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma NCT04659044 Recurrent B-Cel...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory B-Ce...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Mant...
Refractory Marg...
Refractory Smal...
Polatuzumab Ved...
Rituximab
Rituximab and H...
Venetoclax
18 Years - Academic and Community Cancer Research United View Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma NCT00278161 Leukemia
Lymphoma
Pegfilgrastim
Rituximab
Cyclophosphamid...
18 Years - 70 Years Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins View Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy NCT00891137 Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 Years Cellerant Therapeutics View Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma NCT00004192 Lymphoma
Neutropenia
filgrastim
pegfilgrastim
cisplatin
cytarabine
etoposide
methylprednisol...
18 Years - 120 Years University of Nebraska View Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers NCT00003163 Lymphoma
Multiple Myelom...
filgrastim
sargramostim
cyclophosphamid...
melphalan
autologous bone...
peripheral bloo...
radiation thera...
18 Years - National Cancer Institute (NCI) View Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function NCT00118170 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma NCT00007865 Lymphoma
rituximab
carboplatin
etoposide
ifosfamide
19 Years - 120 Years University of Nebraska View Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma NCT00002697 Lymphoma
filgrastim
sargramostim
carboplatin
etoposide
ifosfamide
autologous bone...
bone marrow abl...
peripheral bloo...
radiation thera...
18 Years - 65 Years Memorial Sloan Kettering Cancer Center View Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00244985 Lymphoma
rituximab
pegylated lipos...
18 Years - 120 Years Roswell Park Cancer Institute View Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma NCT00334438 Lymphoma
rituximab
bortezomib
yttrium Y 90 ib...
Indium 111 ibri...
18 Years - 120 Years UNC Lineberger Comprehensive Cancer Center View Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer NCT00003661 Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 Years Roswell Park Cancer Institute View Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma NCT00026429 Leukemia
Lymphoma
denileukin dift...
18 Years - National Cancer Institute (NCI) View Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01812005 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
alisertib
rituximab
laboratory biom...
18 Years - Ohio State University Comprehensive Cancer Center View Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation NCT00003143 Lymphoma
Amifostine
DHAP
18 Years - Jonsson Comprehensive Cancer Center View Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma NCT00082823 Cancer
ziv-aflibercept
18 Years - 120 Years Regeneron Pharmaceuticals View Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma NCT00310167 Lymphoma
radiation thera...
18 Years - University College, London View Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma NCT02446457 Recurrent Diffu...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Laboratory Biom...
Lenalidomide
Pembrolizumab
Rituximab
18 Years - M.D. Anderson Cancer Center View Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies NCT04205409 Recurrent Chron...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Non-H...
Recurrent Plasm...
Refractory Chro...
Refractory Diff...
Refractory Foll...
Refractory Marg...
Refractory Non-...
Refractory Plas...
Recurrent Mantl...
Refractory Mant...
Nivolumab
18 Years - University of Washington View Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia NCT00002908 Leukemia
Lymphoma
bryostatin 1
vincristine sul...
18 Years - Barbara Ann Karmanos Cancer Institute View Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma NCT00848328 Lymphoma
Rituximab
Lenalidomide
18 Years - University of California, Davis View Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma NCT00003356 Lymphoma
aldesleukin
rituximab
18 Years - 75 Years University of Rochester View Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) NCT00005626 Leukemia
Lymphoma
Irinotecan
18 Years - H. Lee Moffitt Cancer Center and Research Institute View Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma NCT00005589 Lymphoma
filgrastim
rituximab
carmustine
cyclophosphamid...
cytarabine
etoposide
melphalan
bone marrow abl...
peripheral bloo...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma NCT00004179 Lymphoma
rituximab
CHOP regimen
cyclophosphamid...
doxorubicin hyd...
prednisone
vincristine sul...
18 Years - 120 Years European Organisation for Research and Treatment of Cancer - EORTC View Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia NCT00005786 Extranodal Marg...
Nodal Marginal ...
Prolymphocytic ...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Margi...
Recurrent Small...
Refractory Chro...
Splenic Margina...
Waldenström Mac...
arsenic trioxid...
laboratory biom...
18 Years - National Cancer Institute (NCI) View Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer NCT00248430 Graft Versus Ho...
Leukemia
Lymphoma
Multiple Myelom...
aldesleukin
therapeutic all...
melphalan
bone marrow abl...
peripheral bloo...
18 Years - 69 Years Fred Hutchinson Cancer Center View Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function NCT00118170 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Mult...
Splenic Margina...
Stage II Multip...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Multi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Unspecified Adu...
Waldenström Mac...
sorafenib tosyl...
pharmacological...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome NCT00002989 Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
busulfan
cyclophosphamid...
idarubicin
melphalan
radiation thera...
16 Years - 60 Years National Cancer Institute (NCI) View Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00040950 Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI) View Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia NCT00062296 Leukemia
Lymphoma
rituximab
epirubicin hydr...
18 Years - Fox Chase Cancer Center View Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma NCT00691652 Lymphoma
rituximab
clofarabine
DNA methylation...
gene expression...
microarray anal...
polymerase chai...
high performanc...
laboratory biom...
18 Years - 89 Years OHSU Knight Cancer Institute View Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928 Adult Non-Hodgk...
Adult Grade III...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Contiguous Stag...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage I Adult B...
Stage I Adult D...
Stage I Adult D...
Stage I Adult D...
Stage I Adult I...
Stage I Adult L...
Stage I Grade 1...
Stage I Grade 2...
Stage I Grade 3...
Stage I Mantle ...
Stage I Margina...
Stage I Small L...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
Waldenstrom Mac...
lenalidomide
rituximab
polymerase chai...
nucleic acid se...
polymorphism an...
flow cytometry
laboratory biom...
18 Years - Case Comprehensive Cancer Center View Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL NCT00732498 Lymphoma
Methylprednisol...
Etoposide
Cytarabine
Cisplatin
Rituximab
In-Zevalin
Y-Zevalin
18 Years - University of Arizona View Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma NCT00002510 Lymphoma
filgrastim
cyclophosphamid...
etoposide
mesna
peripheral bloo...
radiation thera...
16 Years - 65 Years Temple University View Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer NCT02240719 Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Refractory Chro...
Multiple Myelom...
everolimus
bendamustine hy...
18 Years - University of California, Davis View UCN-01 in Treating Patients With Advanced Cancer NCT00003289 Leukemia
Lymphoma
Unspecified Adu...
7-hydroxystauro...
18 Years - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins View Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00110071 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center View Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer NCT00010192 B-cell Adult Ac...
Extranodal Marg...
Nodal Marginal ...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Noncontiguous S...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Splenic Margina...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Adult...
Stage III Grade...
Stage III Grade...
Stage III Grade...
Stage III Mantl...
Stage III Margi...
Stage III Small...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Adult ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Grade ...
Stage IV Mantle...
Stage IV Margin...
Stage IV Small ...
rituximab
aldesleukin
laboratory biom...
pharmacological...
18 Years - National Cancer Institute (NCI) View Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma NCT00002779 Lymphoma
fludarabine pho...
octreotide acet...
18 Years - Alliance for Clinical Trials in Oncology View Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma NCT02281279 B-cell Adult Ac...
Extranodal Marg...
Intraocular Lym...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Recurrent Small...
Refractory Hair...
Small Intestine...
Splenic Margina...
Testicular Lymp...
Waldenström Mac...
rituximab
lenalidomide
romidepsin
laboratory biom...
18 Years - Mayo Clinic View Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma NCT04635683 Recurrent B-Cel...
Recurrent Extra...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Nodal...
Recurrent Splen...
Recurrent Walde...
Refractory B-Ce...
Refractory Extr...
Refractory Foll...
Refractory Grad...
Refractory Grad...
Refractory Grad...
Refractory Lymp...
Refractory Mant...
Refractory Marg...
Refractory Noda...
Refractory Sple...
Refractory Wald...
Lenalidomide
Ublituximab
Umbralisib
18 Years - Ohio State University Comprehensive Cancer Center View PS-341 in Treating Patients With Advanced Cancer NCT00006362 Leukemia
Lymphoma
Multiple Myelom...
Precancerous Co...
Unspecified Adu...
bortezomib
18 Years - Mayo Clinic View Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy NCT00003341 Anemia
Leukemia
Lymphoma
Multiple Myelom...
epoetin alfa
quality-of-life...
18 Years - Memorial Sloan Kettering Cancer Center View Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma NCT00006252 Leukemia
Lymphoma
fludarabine pho...
Cyclophosphamid...
PBSC
G-CSF
Donor lymphocyt...
- 69 Years Alliance for Clinical Trials in Oncology View Bone Marrow Transplantation in Treating Patients With Lymphoma NCT00002829 Lymphoma
Recombinant Int...
Cyclophosphamid...
Etoposide
Mesna
Bone Marrow Tra...
Radiation Thera...
15 Years - 60 Years M.D. Anderson Cancer Center View Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00005592 Lymphoma
90-Y-ibritumoma...
rituximab
indium In 111 i...
18 Years - University of Alabama at Birmingham View Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma NCT00002880 Lymphoma
Etoposide phosp...
- Alliance for Clinical Trials in Oncology View Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma NCT02049541 Extranodal Marg...
Nodal Marginal ...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
PI3K inhibitor ...
rituximab
Pharmacodynamic...
Correlative stu...
18 Years - Ohio State University Comprehensive Cancer Center View Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma NCT00258336 Lymphoma
autologous immu...
rituximab
sargramostim
18 Years - National Cancer Institute (NCI) View Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00040950 Lymphoma
rituximab
agatolimod sodi...
18 Years - National Cancer Institute (NCI) View Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer NCT00782379 Leukemia
Lymphoma
Myelodysplastic...
busulfan
cyclophosphamid...
fludarabine pho...
mycophenolate m...
tacrolimus
allogeneic hema...
peripheral bloo...
18 Years - 60 Years Northside Hospital, Inc. View Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma NCT01849263 Grade 3a Follic...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Refractory Foll...
Ibrutinib
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer NCT00003661 Graft Versus Ho...
Leukemia
Lymphoma
Myelodysplastic...
Neuroblastoma
anti-thymocyte ...
busulfan
cyclosporine
melphalan
methylprednisol...
umbilical cord ...
radiation thera...
- 54 Years Roswell Park Cancer Institute View Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00110071 Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
fludarabine pho...
peripheral bloo...
iodine I 131 to...
laboratory biom...
flow cytometry
polymerase chai...
60 Years - Fred Hutchinson Cancer Center View Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT00073918 Anaplastic Larg...
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Mantl...
Recurrent Margi...
Splenic Margina...
Waldenström Mac...
cyclophosphamid...
etoposide
iodine I 131 to...
quality-of-life...
peripheral bloo...
18 Years - 60 Years Fred Hutchinson Cancer Center View Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma NCT00551239 Leukemia
Lymphoma
rituximab
fludarabine pho...
pixantrone dima...
18 Years - 120 Years CTI BioPharma View